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Abstract
Background: Inflammation is a well-known risk factor for the development of choroidal neovascularization (CNV),
yet not all causes of intraocular inflammation have been documented to cause CNV. Tubulointerstitial nephritis and
uveitis syndrome (TINU) is a rare cause of intraocular inflammation mostly in pediatric patients and only seldom has
been associated with development of CNV.
Findings: A 34-year-old pregnant female with a past history of bilateral ocular inflammation secondary to TINU
presents 1 year after diagnosis with vision loss in the left eye. Clinical examination and investigations show the
development of CNV in the left eye. The patient was treated with ranibizumab (Genentech, San Francisco, CA)
intravitreal injections with improvement in symptoms and clinical findings.
Conclusions: We report the first case of CNV secondary to TINU in an adult patient. The CNV associated with TINU
is responsive to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.
Findings
Introduction
Various conditions that lead to intraocular inflammation
can be associated with the development of choroidal
neovascularization (CNV) [1, 2]. Tubulointerstitial neph-
ritis and uveitis syndrome (TINU) is a rare entity first
described in 1975 by Dobrin and colleagues [3], and has
seldom been associated with secondary CNV [4]. Since
TINU was first described, there have been more than
150 cases reported mostly in the pediatric nephrology
and ophthalmology literature [5, 6]. To date, however,
there have been only two documented cases of CNV sec-
ondary to TINU reported in the literature [4] with both
of these cases in pediatric patients. Herein we report a
case of CNV secondary to TINU in an adult patient
which to our knowledge is the first such to be described.
Case description
A 34-year-old pregnant female at 33 weeks gestation
presented as a consult to the retina service with chief
complaint of sudden decreased vision in the left eye
beginning 1 month ago. The patient was first diagnosed
with TINU 1 year prior by a uveitis specialist. At that
time, she had presented with an inflamed, painful left
eye, 2+ cell and flare, posterior synechiae, and a nega-
tive work up—including rapid plasma reagin, quanti-
FERON Gold test, FTA-ABS, human leukocyte antigen
(HLA)-B27 analysis by flow cytometry, and Lyme titers.
Serum beta 2-microglobulin was found to be 2.43 (nor-
mal <1.80 mg/dl), and urine beta 2-microglobuin was
found to be 4.70 mg/dl (normal <0.24 mg/dl). Based on
the clinical picture and laboratory findings, a diagnosis
of TINU was made and the patient was referred to
nephrology for renal evaluation. The patient was subse-
quently lost to follow-up.
On her presentation to the retina service, the patient’s
best corrected visual acuity was found to be 20/500 in
her left eye. The anterior segment examination was sig-
nificant for pigment on the anterior capsule of the lenses
bilaterally consistent with prior inflammation. There was
no active intraocular inflammation in either eye. Her di-
lated fundus exam of the left eye was significant for cen-
tral thickening of the macula with pinpoint parafoveal
hemorrhage (Fig. 1a). Spectral-domain optical coherence
tomography (SD-OCT) imaging showed distortion of
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foveal contour and a break in Bruch’s membrane with
disruption of overlying photoreceptors consistent with
choroidal neovascularization (Fig. 2a). Fluorescein angi-
ography was deferred as the patient was pregnant. To
support further the diagnosis of TINU, the patient was
tested for HLA-DRB1*0102 and the result was positive
for subtype DR1,8; DQ 4,5. The patient was offered
intraocular anti-vascular endothelial growth factor (anti-
VEGF) therapy or intraocular steroids; however, follow-
ing discussion of the risks, benefits, and alternatives, the
patient declined any treatment until after delivery.
The patient delivered at 40 weeks gestation and was
seen 3 days post-partum. The patient’s visual acuity,
exam, and SD-OCT were unchanged. Fluorescein angi-
ography was obtained which revealed leakage consist-
ent with a diagnosis of CNV (Fig. 1b). The patient was
not breastfeeding and was treated with two intravitreal
injections of ranibizumab at 1 month apart. At the most
recent follow-up 8 weeks following the first injection,
BCVA improved to 20/50 in the left eye. OCT imaging
showed consolidation of the choroidal neovascularization
(Fig. 2b).
Fig. 1 a Color fundus photo of left eye shows pinpoint hemorrhage overlying the fovea. b Fluorescein angiography of left eye demonstrates late
phase parafoveal leakage consistent with neovascularization
Fig. 2 a SD-OCT image through fovea reveals disruption of Bruch’s membrane and overlying photoreceptor layer. b SD-OCT image demonstrating
consolidation of choroidal neovascularization post-treatment with ranibizumab
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Discussion
Tubulointerstitial nephritis and uveitis is an uncommon
entity that is described mostly in children with a median
age of diagnosis of 15 years and has a 3:1 female pre-
dominance [7, 8]. Establishing the diagnosis of TINU is
challenging and requires clinical suspicion. No specific
laboratory study is diagnostic of TINU, but there are
several laboratory abnormalities that suggest the diagno-
sis in the proper clinical context. Patients with TINU
have been reported to have anemia, eosinophilia, eleva-
tions in ESR and CRP, sterile pyuria and abnormal eleva-
tions in serum, and urine beta-2 microglobulin [9, 10].
Renal disease can be confirmed by biopsy, which shows
tubulointerstitial edema and infiltration of lymphocytes,
plasma cells and histiocytes, but this is only rarely done
[11]. More recently, a strong association has been shown
between TINU and the HLA-DRB1*0102 [10]. The diag-
nosis of TINU was made clinically in our patient with
demonstration of bilateral anterior uveitis, elevated serum
and urine beta-2 microglobulin, and otherwise negative
workup for other causes of uveitis. As an additional meas-
ure, we tested the patient for HLA-DRB1*0102. The
positive result strongly supports the clinical diagnosis of
TINU.
Generally, the ocular inflammation of TINU prefer-
entially affects the anterior segment, although posterior
inflammation has been reported [4–8]. Intraocular in-
flammation is a well-established risk factor for the
development of CNV and has been described in associ-
ation with a wide variety of inflammatory conditions
including multifocal choroiditis and uveitis syndrome,
punctate inner choroidopathy, and ocular histoplasmo-
sis [1, 2]. Rarely has CNV been described secondary to
TINU and only in the pediatric population [4]. Our
patient clearly demonstrated SD-OCT and angiographic
evidence of choroidal neovascularization in the absence
of other identifiable causes. This is the first reported
case of CNV secondary to TINU in an adult, and as
such, patients should be counseled and monitored for
the occurrence of this rare complication.
Multiple studies have demonstrated the efficacy of
anti-VEGF therapy in the treatment of CNV due to
age-related macular degeneration [12, 13]. There are,
however, no established guidelines for treatment of in-
flammatory CNV. The small number of patients with
these rare conditions preclude the possibility of large
randomized trials to evaluate treatment efficacy. A
recent review, however, evaluated 16 studies of anti-
VEGF therapy for CNV secondary to non-age-related
macular degeneration conditions and concluded that
positive treatment outcomes in these patients should en-
courage clinicians to consider bevacizumab and ranibizu-
mab for rare causes of CNV [14]. We conclude based on
these considerations, and the favorable outcome for our
patient, that treatment with anti-VEGF should be consid-
ered as these lesions appear to show a favorable response
to treatment.
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